Skip to content

Medical emergency? What to do

Weight-loss drugs may harm developing brain: study

3-RXPublished May 9, 20083 min read

Key points

  • A drug from a new class of weight-loss treatments disrupted wiring needed for brain development in young mice, U.S. researchers said on Wednesday, raising concerns about using such medications in children.
  • "I think that the cautionary note is that these mechanisms play an important role in ... brain development," said Bear, whose study appears in the journal Neuron.
  • Other drugmakers, including Merck & Co Inc, are working on similar drugs.
  • Bear said these cannabinoid receptors are known to regulate signals between neurons, and his team wanted to see if they would have an effect on plasticity in these young mice.

A drug from a new class of weight-loss treatments disrupted wiring needed for brain development in young mice, U.S. researchers said on Wednesday, raising concerns about using such medications in children.

Mark Bear and colleagues at the Massachusetts Institute of Technology studied the effects of a chemical that suppresses appetite by blocking cannabinoid receptors in the brain, the same brain mechanisms that make people hungry when they smoke marijuana.

"I think that the cautionary note is that these mechanisms play an important role in ... brain development," said Bear, whose study appears in the journal Neuron.

Sanofi-Aventis' weight-loss pill rimonabant, also known as Zimulti and sold under the brand name Acomplia in Europe, is the first in this new class of drugs. A U.S. expert panel rejected it last June because of fears it might trigger suicidal thoughts.

Other drugmakers, including Merck & Co Inc, are working on similar drugs.

Bear's team at MIT was hoping to gain insight into how the brain adapts and rewires itself through learned experiences. This so-called plasticity is central to the development of neurons in the brain of children and young animals.

Bear said these cannabinoid receptors are known to regulate signals between neurons, and his team wanted to see if they would have an effect on plasticity in these young mice.

They were specifically testing learning in the visual cortex of the mouse, a part of the brain that processes information gathered from what they see.

ADAPTING TO CHANGE

Their experiments tested how well the animals adapted if one eye was closed.

The researchers did not use rimonabant in the study. Instead, they used a chemical analog or copy -- in this case a drug available for laboratory use known as AM 251.

When they gave the mice AM 251 to block their cannabinoid receptors, the animals still behaved as if both eyes were open. This suggested the visual cortex was not adapting as it should.

"Our finding of a profound disruption of cortical plasticity in juvenile mice treated with AM 251 suggests caution is advised in the use of such compounds in children," the researchers wrote.

Bear said the finding is similar to the situation with many drugs.

"You have to weigh the benefits against the risks. If the benefit is related more to vanity than morbidity, I don't think the risks are tolerable," he said.

Sanofi-Aventis spokeswoman Julissa Viana said rimonabant is not approved for use in children.

"At this point in time it is approved for use in adults who are overweight and obese with cardiovascular risk factors," she said. "We don't encourage its use in children and it has not been studied nor is it indicated for use in children."

The finding is the latest blow for rimonabant, which once was predicted to be a multibillion-dollar seller.

A study last month of the drug in obese heart patients found more than 40 percent of patients who took the drug developed psychiatric problems.

But last month the drugmaker Sanofi said it still believes Acomplia can be a winner and reiterated plans to submit the drug worldwide as a treatment for type 2 diabetes in 2009.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBrainWeight Loss

Keep reading

Brain

New treatment dissolves blood clots in brain tissue

A new treatment that treats a subset of stroke patients by combining minimally invasive surgery, an imaging technique likened to "GPS for the brain," and the clot-busting drug t-PA appears to be safe and effective,…

3 min read

Brain

Spring-cleaning the mind?

Lapses in memory occur more frequently with age, yet the reasons for this increasing forgetfulness have not always been clear. According to new research from Concordia University, older individuals have reduced…

3 min read

Brain

Research Explores Little-Understood Brain Disease

The population of aged persons worldwide is expanding rapidly, and it is becoming increasingly clear that there are many different diseases that affect the minds of these individuals. Researchers at the University of…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.